Charles L. Bennett, M.D., Ph.D., M.P.P., Stefano Luminari, M.D., Allen R. Nissenson, M.D., Martin S. Tallman, M.D., Stephen A. Klinge, B.A., Norene McWilliams, J.D., M.P.H., June M. McKoy, M.D., J.D., M.P.H., Benjamin Kim, M.D., E. Allison Lyons, B.A., Steve M. Trifilio, R.P.H., Dennis W. Raisch, Ph.D., Andrew M. Evens, D.O., Timothy M. Kuzel, M.D., Glen T. Schumock, Pharm.D., M.B.A., Steven M. Belknap, M.D., Francesco Locatelli, M.D., Jerôme Rossert, M.D., Ph.D., and Nicole Casadevall, M.D.
Background Between 1988 and 1998, antibody-associated pure red-cellaplasia was reported in three patients who had undergone treatmentwith recombinant human erythropoietin (epoetin). Between 1998and 2000, 13 such cases were reported from France — 12in patients who had received the Eprex formulation of epoetinalfa and 1 in a patient who had received Neorecormon (a formulationof epoetin beta); both are products that are marketed outsidethe United States.
Methods We obtained reports of epoetin-associated pure red-cellaplasia from the Food and Drug Administration and from the manufacturersof Eprex, Epogen (another formulation of epoetin alfa), andNeorecormon. The numbers of case reports and estimates of exposure-adjustedincidence were analyzed according to the product, the causeof anemia, the route of administration, the country in whichpure red-cell aplasia was identified, and the date on whichpure red-cell aplasia was reported.
Results Between January 1998 and April 2004, 175 cases of epoetin-associatedpure red-cell aplasia were reported for Eprex, 11 cases forNeorecormon, and 5 cases for Epogen. Over half these cases hadoccurred in France, Canada, the United Kingdom, and Spain. Between2001 and 2003, the estimated exposure-adjusted incidence was18 cases per 100,000 patient-years for the Eprex formulationwithout human serum albumin, 6 per 100,000 patient-years forthe Eprex formulation with human serum albumin, 1 case per 100,000patient-years for Neorecormon, and 0.2 case per 100,000 patient-yearsfor Epogen. After procedures were adopted to ensure appropriatestorage, handling, and administration of Eprex to patients withchronic kidney disease, the exposure-adjusted incidence decreasedby 83 percent worldwide.
Conclusions After the peak incidence of Eprex-associated purered-cell aplasia was reached in 2001, interventions designedin response to drug-monitoring programs worldwide resulted ina reduction of more than 80 percent in the incidence of purered-cell aplasia due to Eprex.
Source Information
From the Midwest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center (C.L.B.); Division of Hematology and Oncology (C.L.B., M.S.T., A.M.E., T.M.K.), Division of Geriatrics (J.M.M.), and Division of General Internal Medicine (S.M.B.), all in the Department of Medicine (B.K.); and Institute for Health Services Research and Policy Studies (C.L.B., S.A.K., N.M., E.A.L.), Northwestern University, Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center of Northwestern University (C.L.B., M.S.T., A.M.E., T.M.K.); Department of Pharmacy, Northwestern Memorial Hospital (S.T.); and Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago (G.T.S.) — all in Chicago; Dipartimento di Oncologia ed Ematologia, Università di Modena e Reggio Emilia, Modena, Italy (S.L.); Division of Nephrology, David Geffen School of Medicine at the University of California, Los Angeles (A.R.N.); Veterans Affairs Cooperative Study Program Clinical Research Pharmaceutical Coordinating Center, University of New Mexico, Albuquerque (D.W.R.); Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy (F.L.); and Department of Nephrology, Tenon Hospital, Pierre and Marie Curie University (J.R.); and Department of Hematology, Hôtel-Dieu, and INSERM Unité 352 (N.C.) — all in Paris.
Address reprint requests to Dr. Bennett at the Midwest Center for Health Services and Policy Research, Jesse Brown Veterans Affairs Medical Center, 333 E. Huron St., Suite 277, Chicago, IL 60611, or at cbenne{at}northwestern.edu.
Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliege, A.-M., Froissart, M., Eckardt, K.-U.
(2009). A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. NEJM
361: 1848-1855
[Abstract][Full Text]
Bunn, H. F.
(2009). End Run around Epo. NEJM
361: 1901-1903
[Full Text]
Haljan, G., Maitland, A., Buchan, A., Arora, R. C., King, M., Haigh, J., Culleton, B., Faris, P., Zygun, D.
(2009). The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled, Proof-of-Concept Clinical Trial. Stroke
40: 2769-2775
[Abstract][Full Text]
Scrijvers, D., Roila, F., On behalf of the ESMO Guidelines Working Group,
(2009). Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use. Ann Oncol
20: iv159-iv161
[Full Text]
Schellekens, H.
(2009). Biosimilar therapeutics--what do we need to consider?. NDT Plus
2: i27-i36
[Abstract][Full Text]
Summers, S., Holdsworth, S., Sharples, E.
(2008). The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant
23: 3053-3055
[Full Text]
Mellstedt, H., Niederwieser, D., Ludwig, H.
(2008). The challenge of biosimilars. Ann Oncol
19: 411-419
[Abstract][Full Text]
Pollock, C., Johnson, D. W., Horl, W. H., Rossert, J., Casadevall, N., Schellekens, H., Delage, R., De Francisco, A., Macdougall, I., Thorpe, R., Toffelmire, E.
(2008). Pure Red Cell Aplasia Induced by Erythropoiesis-Stimulating Agents. CJASN
3: 193-199
[Abstract][Full Text]
Singh, A. K.
(2008). Anemia of Chronic Kidney Disease. CJASN
3: 3-6
[Full Text]
Jelkmann, W.
(2007). Recombinant EPO production points the nephrologist should know. Nephrol Dial Transplant
22: 2749-2753
[Full Text]
Bennett, C. L., Kim, B., Zakarija, A., Bandarenko, N., Pandey, D. K., Buffie, C. G., McKoy, J. M., Tevar, A. D., Cursio, J. F., Yarnold, P. R., Kwaan, H. C., De Masi, D., Sarode, R., Raife, T. J., Kiss, J. E., Raisch, D. W., Davidson, C., Sadler, J. E., Ortel, T. L., Zheng, X. L., Kato, S., Matsumoto, M., Uemura, M., Fujimura, Y.
(2007). Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura: A Report From the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol
50: 1138-1143
[Abstract][Full Text]
Lenga, I., Lok, C., Marticorena, R., Hunter, J., Dacouris, N., Goldstein, M.
(2007). Role of Oral Iron in the Management of Long-Term Hemodialysis Patients. CJASN
2: 688-693
[Abstract][Full Text]
Locatelli, F., Del Vecchio, L., Pozzoni, P.
(2007). PURE RED-CELL APLASIA "EPIDEMIC"--MYSTERY COMPLETELY REVEALED?. pdi
27: S303-S307
[Abstract][Full Text]
Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W.
(2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med
167: 1041-1049
[Abstract][Full Text]
Manenti, L., Vaglio, A.
(2007). Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin-{beta}. Nephrol Dial Transplant
22: 1465-1467
[Full Text]
Stuve, O., Marra, C. M., Cravens, P. D., Singh, M. P., Hu, W., Lovett-Racke, A., Monson, N. L., Phillips, J. T., Tervaert, J. W. C., Nash, R. A., Hartung, H.-P., Kieseier, B. C., Racke, M. M., Frohman, E. M., Hemmer, B.
(2007). Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions. Arch Neurol
64: 169-176
[Abstract][Full Text]
Bunn, H. F.
(2007). New agents that stimulate erythropoiesis. Blood
109: 868-873
[Abstract][Full Text]
Zumberg, M. S., Leissinger, C.
(2007). Acquired underproduction anemias. ASH-SAP
2007: 78-101
[Full Text]
Jacob, A., Sandhu, K., Nicholas, J., Jones, H., Odum, J., Rylance, P., Carmichael, P., Jackson, M., Handa, S., Macwhannell, A., Basu, S., Wahid, F., Casadevall, N., Mufti, G., Macdougall, I.
(2006). Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant
21: 2963-2965
[Full Text]
Giannouli, S, Voulgarelis, M, Ziakas, P D, Tzioufas, A G
(2006). Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis
65: 144-148
[Abstract][Full Text]
Bennett, C. L., Cournoyer, D., Carson, K. R., Rossert, J., Luminari, S., Evens, A. M., Locatelli, F., Belknap, S. M., McKoy, J. M., Lyons, E. A., Kim, B., Sharma, R., Costello, S., Toffelmire, E. B., Wells, G. A., Messner, H. A., Yarnold, P. R., Trifilio, S. M., Raisch, D. W., Kuzel, T. M., Nissenson, A., Lim, L.-C., Tallman, M. S., Casadevall, N.
(2005). Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood
106: 3343-3347
[Abstract][Full Text]
Engert, A.
(2005). Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol
16: 1584-1595
[Abstract][Full Text]
Lippin, Y., Dranitzki-Elhalel, M., Brill-Almon, E., Mei-Zahav, C., Mizrachi, S., Liberman, Y., Iaina, A., Kaplan, E., Podjarny, E., Zeira, E., Harati, M., Casadevall, N., Shani, N., Galun, E.
(2005). Human erythropoietin gene therapy for patients with chronic renal failure. Blood
106: 2280-2286
[Abstract][Full Text]
Bennett, C. L., Nebeker, J. R., Raisch, D. W.
(2005). The RADAR Project and the FDA--Reply. JAMA
294: 1206-1207
[Full Text]
Cooper, C., Sears, W., Bienzle, D.
(2005). Reticulocyte changes after experimental anemia and erythropoietin treatment of horses. J. Appl. Physiol.
99: 915-921
[Abstract][Full Text]
Stasi, R., Amadori, S., Littlewood, T. J., Terzoli, E., Newland, A. C., Provan, D.
(2005). Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns. The Oncologist
10: 539-554
[Abstract][Full Text]
Longo, D. L.
(2005). Closing in on a Killer: Anemia in Elderly People. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
60: 727-728
[Full Text]
Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennett, C., Engert, A.
(2005). Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis. JNCI J Natl Cancer Inst
97: 489-498
[Abstract][Full Text]
Weiss, G., Goodnough, L. T.
(2005). Anemia of Chronic Disease. NEJM
352: 1011-1023
[Full Text]
Praditpornsilpa, K., Buranasot, S., Bhokaisuwan, N., Avihingsanon, Y., Pisitkul, T., Kansanabuch, T., Eiam-Ong, S., Chusil, S., Intarakumtornchai, T., Tungsanga, K.
(2005). Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation. Nephrol Dial Transplant
20: 626-630
[Full Text]
Braun, M.M., Wise, R. P., Wood, J. J., Bennett, C., Casadevall, N., Cournoyer, D.
(2005). Epoetin and Pure Red-Cell Aplasia. NEJM
352: 511-512
[Full Text]
Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Hunkler, R. J., Hontz, K. M.
(2005). Projecting future drug expenditures--2005. Am J Health Syst Pharm
62: 149-167
[Abstract][Full Text]
Maiese, K., Li, F., Chong, Z. Z.
(2005). New Avenues of Exploration for Erythropoietin. JAMA
293: 90-95
[Abstract][Full Text]
Previous
